Intended for healthcare professionals


Serious Fraud Office launches criminal inquiry into GlaxoSmithKline

BMJ 2014; 348 doi: (Published 29 May 2014) Cite this as: BMJ 2014;348:g3612
  1. Adrian O’Dowd
  1. 1London

The United Kingdom’s major fraud body has launched a criminal investigation into the drug company GlaxoSmithKline (GSK). The Serious Fraud Office inquiry, announced on 27 May, will focus on the commercial practices of GSK and its subsidiaries and comes just weeks after the company was accused of bribery in China.1

The BMJ understands that the new investigation will look at …

View Full Text

Log in

Log in through your institution


* For online subscription